Personalis Reports Second Quarter 2021 Financial Results
Personalis, Inc. (Nasdaq: PSNL) reported record revenue of $21.7 million for Q2 2021, an 11% increase from $19.5 million in Q2 2020. The revenue from biopharma and other customers, excluding the VA MVP, grew 72% to $8.2 million. The company ended the quarter with cash and investments totaling $328.9 million. Despite achieving growth, Personalis faced a net loss of $15 million and an anticipated net loss of $65 million to $70 million for 2021. Looking ahead, Q3 revenue is expected to be around $22.2 million.
- Record revenue of $21.7 million in Q2 2021, an 11% increase YoY.
- Revenue from biopharma and other customers increased 72% to $8.2 million.
- Achieved delivery of over 125,000 whole human genome sequences.
- Net loss of $15 million in Q2 2021, up from a net loss of $9.3 million YoY.
- Operating expenses rose to $23.1 million, compared to $14.2 million in the prior year.
- Expected net loss for full year of 2021 between $65 million and $70 million.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported financial results for the second quarter ended June 30, 2021.
Second Quarter and Recent Highlights
-
Record quarterly revenue of
$21.7 million in the second quarter of 2021 compared with$19.5 million in the second quarter of 2020, an11% increase -
Revenue of
$8.2 million from biopharma and all other customers, excluding the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP), in the second quarter of 2021 compared with$4.7 million in the second quarter of 2020, a72% increase -
Ended the second quarter with cash, cash equivalents, and short-term investments of
$328.9 million as of June 30, 2021 - Achieved milestone of delivering more than 125,000 whole human genome sequences to the VA MVP
“I’m proud to say that we were able to report record revenue once again this quarter and that we achieved our twentieth consecutive quarter of growth, as we converted an increasing number of orders into revenue. Revenue from biopharma and all other customers grew
Second Quarter 2021 Financial Results
Revenue was
Gross margin was
Operating expenses were
Net loss was
Business Outlook
Personalis expects the following for the third quarter of 2021:
-
Total revenue to be approximately
$22.2 million -
Revenue from biopharma and all other customers, excluding VA MVP, to be in the range of
$7.5 million to$8.5 million -
Net Loss to be in the range of
$17 million to$18 million ; estimated outstanding shares of 44 million
Personalis expects the following for the full year of 2021:
-
Total revenue to be approximately
$85 million -
Revenue from biopharma and all other customers, excluding VA MVP, to be in the range of
$33 million to$34 million -
Net Loss to be in the range of
$65 million to$70 million ; estimated outstanding shares of 44 million
Webcast and Conference Call Information
Personalis will host a conference call to discuss the second quarter 2021 financial results after market close on Wednesday, August 4, 2021 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live over the phone by dialing (866) 220-8061 for U.S. callers or (470) 495-9168 for international callers, using the conference ID: 8564509. The live webinar can be accessed at https://investors.personalis.com.
About Personalis, Inc.
Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT PlatformTM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing laboratories globally and is currently the sole sequencing provider to the VA MVP. To enable cancer and population sequencing, the Personalis Clinical Laboratory is built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the results predicted, and reported results should not be considered an indication of future performance. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “estimate,” “expect,” “should,” “target,” “will,” or “would” or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements regarding the company’s expectations for revenue and net loss for the third quarter and full year of 2021. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors relate to, among others: the timing and pace of new orders from customers, including from the U.S. Department of Veterans Affairs Million Veteran Program, which was the company’s largest customer in 2018, 2019, and 2020; the launch of new products and new product features, such as NeXT Personal; the market adoption of offerings launched in 2020, such as Personalis’ whole exome liquid biopsy product; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter over quarter and year over year; whether orders for the NeXT Platform and revenue from biopharmaceutical customers increase in future periods; the success of Personalis’ collaborations; the success of the company’s international expansion plans; the evolution of cancer therapies and market adoption of the company’s services; the company’s expectations regarding future performance; and the ongoing COVID-19 pandemic, which may significantly impact the company’s business and operations and the business and operations of our customers and suppliers. In addition, other potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those risks and uncertainties included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the period ended June 30, 2021 that will be filed after this earnings release, and risk factors included within the Annual Report on Form 10-K filed on February 25, 2021. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.
PERSONALIS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) |
||||||||||||||||
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
||||
Revenue |
|
$ |
21,670 |
|
|
$ |
19,495 |
|
|
$ |
42,551 |
|
|
$ |
38,656 |
|
Costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
|
13,502 |
|
|
|
14,823 |
|
|
|
26,956 |
|
|
|
29,945 |
|
Research and development |
|
|
11,687 |
|
|
|
6,465 |
|
|
|
21,183 |
|
|
|
12,855 |
|
Selling, general and administrative |
|
|
11,428 |
|
|
|
7,705 |
|
|
|
21,849 |
|
|
|
14,979 |
|
Total costs and expenses |
|
|
36,617 |
|
|
|
28,993 |
|
|
|
69,988 |
|
|
|
57,779 |
|
Loss from operations |
|
|
(14,947 |
) |
|
|
(9,498 |
) |
|
|
(27,437 |
) |
|
|
(19,123 |
) |
Interest income |
|
|
103 |
|
|
|
246 |
|
|
|
198 |
|
|
|
756 |
|
Interest expense |
|
|
(65 |
) |
|
|
— |
|
|
|
(65 |
) |
|
|
(2 |
) |
Other income (expense), net |
|
|
(36 |
) |
|
|
1 |
|
|
|
(48 |
) |
|
|
9 |
|
Loss before income taxes |
|
|
(14,945 |
) |
|
|
(9,251 |
) |
|
|
(27,352 |
) |
|
|
(18,360 |
) |
Provision for income taxes |
|
|
8 |
|
|
|
4 |
|
|
|
5 |
|
|
|
34 |
|
Net loss |
|
$ |
(14,953 |
) |
|
$ |
(9,255 |
) |
|
$ |
(27,357 |
) |
|
$ |
(18,394 |
) |
Net loss per share, basic and diluted |
|
$ |
(0.34 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.63 |
) |
|
$ |
(0.58 |
) |
Weighted-average shares outstanding, basic and diluted |
|
|
43,960,794 |
|
|
|
31,731,628 |
|
|
|
43,113,195 |
|
|
|
31,538,329 |
|
PERSONALIS, INC. SUPPLEMENTAL REVENUE INFORMATION (unaudited) (in thousands) |
||||||||||||
|
|
Three Months Ended June 30, |
|
Six Months Ended June 30, |
||||||||
|
|
2021 |
|
2020 |
|
2021 |
|
2020 |
||||
VA MVP |
|
$ |
13,507 |
|
$ |
14,750 |
|
$ |
26,717 |
|
$ |
29,506 |
All other customers |
|
|
8,163 |
|
|
4,745 |
|
|
15,834 |
|
|
9,150 |
Total revenue |
|
$ |
21,670 |
|
$ |
19,495 |
|
$ |
42,551 |
|
$ |
38,656 |
PERSONALIS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands, except share and per share data) |
||||||||
|
|
June 30, 2021 |
|
December 31, 2020 |
||||
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
70,080 |
|
|
$ |
68,525 |
|
Short-term investments |
|
|
258,827 |
|
|
|
134,765 |
|
Accounts receivable, net |
|
|
9,278 |
|
|
|
6,349 |
|
Inventory and other deferred costs |
|
|
7,321 |
|
|
|
5,639 |
|
Prepaid expenses and other current assets |
|
|
8,803 |
|
|
|
5,441 |
|
Total current assets |
|
|
354,309 |
|
|
|
220,719 |
|
Property and equipment, net |
|
|
14,258 |
|
|
|
11,834 |
|
Operating lease right-of-use assets |
|
|
11,126 |
|
|
|
10,271 |
|
Other long-term assets |
|
|
3,647 |
|
|
|
2,018 |
|
Total assets |
|
$ |
383,340 |
|
|
$ |
244,842 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
8,919 |
|
|
$ |
8,301 |
|
Accrued and other current liabilities |
|
|
13,708 |
|
|
|
11,301 |
|
Contract liabilities |
|
|
11,460 |
|
|
|
21,034 |
|
Total current liabilities |
|
|
34,087 |
|
|
|
40,636 |
|
Long-term operating lease liabilities |
|
|
8,518 |
|
|
|
8,541 |
|
Other long-term liabilities |
|
|
1,988 |
|
|
|
720 |
|
Total liabilities |
|
|
44,593 |
|
|
|
49,897 |
|
Commitments and Contingencies |
|
|
|
|
|
|
|
|
Stockholders’ equity |
|
|
|
|
|
|
|
|
Preferred stock, |
|
|
— |
|
|
|
— |
|
Common stock, |
|
|
4 |
|
|
|
4 |
|
Additional paid-in capital |
|
|
547,951 |
|
|
|
376,788 |
|
Accumulated other comprehensive income (loss) |
|
|
18 |
|
|
|
22 |
|
Accumulated deficit |
|
|
(209,226 |
) |
|
|
(181,869 |
) |
Total stockholders’ equity |
|
|
338,747 |
|
|
|
194,945 |
|
Total liabilities and stockholders’ equity |
|
$ |
383,340 |
|
|
$ |
244,842 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005894/en/
FAQ
What were Personalis' financial results for Q2 2021?
What is the projected revenue for Personalis in Q3 2021?
What is the net loss forecast for Personalis for the full year 2021?
How much cash did Personalis have at the end of Q2 2021?
